Navigation Links
OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Date:3/4/2010

BOTHELL, WA and VANCOUVER, WA, March 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and fiscal year 2009 financial results will be released at the market close on Monday, March 8, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's financial results and provide a 2010 corporate outlook.

A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at http://ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-604-9670 (U.S. & Canada) or 719-325-4746 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at www.oncogenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.

Back to top
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
2. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
3. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
4. OncoGenex Reports Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
7. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
8. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
9. OncoGenex Reports Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
Breaking Biology Technology:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):